LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Trial ID or NCT#

NCT03711929

Status

recruiting iconRECRUITING

Purpose

This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS). There is a 6-month, single-arm, open-label period after completion of the 6-month double- masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.

Official Title

LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. Non-Infectious Active Uveitis of the Posterior Segment
Exclusion Criteria:
  1. Females who are pregnant, nursing, or planning a pregnancy Confirmed or suspected infectious uveitis
View All Criteria
Show Less

Investigator(s)

Diana Do, MD
Diana Do, MD
Retina specialist, Ophthalmologist
Professor of Ophthalmology

View on ClinicalTrials.gov